@ShahidNShah
Sema4 Acquires GeneDx for $623M to Strengthen AI-Driven Genomic Platform
Today, Sema4 (Nasdaq: SMFR), a health intelligence company, announced it has signed a definitive agreement to acquire GeneDx, a leader in genomic testing and analysis, at a purchase price representing approximately $623 million, strengthening its market-leading health intelligence and genomic screening offerings. In connection with the acquisition, Sema4 has also entered into definitive agreements for a private placement financing to sell $200 million in Class A common stock at a price of $4.00 per share from a syndicate of institutional investors, including Pfizer. The companies expect to complete the acquisition in the second quarter of 2022, positioning Sema4 to grow and scale its genomic offerings and further transform the standard of care in health systems and for patients throughout their lives. Dr. Schadt will continue to serve Sema4 as co-CEO and as a member of the Board of Directors focusing on leading R&D and the IT platform components of Sema4, the strategic development of Sema4’s health intelligence capabilities, and partnerships with health systems and biopharma companies.
Continue reading at hitconsultant.net
Make faster decisions with community advice
- HHS, DOD and vendors partner for critical care via telehealth
- How AI and machine learning can help predict SDOH needs
- Microsoft, Cleveland Clinic and Providence join coalition to innovate AI in healthcare
- ONC Publishes the Trusted Exchange Framework and the Common Agreement
- Why providers are key to digital therapeutic uptake?
Next Article
-
Why providers are key to digital therapeutic uptake?
Plus, digital therapeutics could help mitigate a shortage of clinicians like physicians, nurses and mental health professionals, said Chris Wasden, head of HappifyDTx at Happify Health. Patients can …
Posted Jan 18, 2022 Digital Therapeutics